In February 2026, the National Institute on Drug Abuse made the first federal award to study psilocybin as it is actually delivered to the public rather than as it is administered inside a clinical trial. The grant, NIDA award R01DA060253, is a five-year, $3.3 million project led by researchers at Oregon Health and Science University and the Legacy Research Institute in Portland, operating as the Oregon Psychedelic Evaluation Nexus, or OPEN, co-directed by Adie Rae and Todd Korthuis. It is the first federally funded work to assess legal psychedelic services delivered in community settings. The detail that matters is not the dollar figure. It is what the study measures, and why no clinical trial can measure it.
What the study looks at
Oregon approved supervised psilocybin services through a 2020 ballot measure and began permitting access for adults 21 and older in 2023. The OPEN project treats that program as a natural experiment. Rather than recruiting a screened cohort into a clinic, the researchers are enrolling people who are already using Oregon’s licensed psilocybin services, targeting more than 1,600 participants out of an estimated 15,000 who have gone through the program, and following them with surveys and interviews over the 12 months after their session. The primary questions are about safety and substance use, whether and how access to psilocybin services changes participants’ use of alcohol, nicotine, and other substances over time, alongside symptom change, side effects, and the difficult experiences clients should be prepared for.
That framing is itself worth noting. This is a NIDA grant built around substance use, not a depression-efficacy study, which places it squarely inside the pattern of where federal psychedelic money has been going.
Why a trial cannot do this
Every psychedelic dataset that has shaped the field so far comes from controlled trials with tight inclusion criteria, fixed doses, structured therapeutic support, and careful screening that excludes most of the people who would actually seek the treatment. OHSU researchers estimate that since the 1950s, only about 3,000 individuals have taken part in all psychedelic clinical trials combined. Oregon’s program is already larger than that and growing, and its clients are not screened the way trial participants are. They are self-selected, varied in their conditions and motivations, and treated in diverse settings by a range of providers.
This is the gap the OPEN study fills, and it is the gap the desk has flagged repeatedly in its work on psychedelic trial design. A controlled trial answers whether a drug can work under ideal and tightly managed conditions. It does not answer whether the same effect appears when the drug is delivered the way a state program delivers it, to people the trial would have excluded, without the blinding and structure that may be carrying part of the measured benefit. The persistent question about psychedelic trials is whether their effects generalize beyond the conditions that produced them. An observational study of thousands of real-world users is the first instrument capable of testing that, on safety at least, at meaningful scale.
What it cannot establish
The same design that gives the study its reach limits what it can prove. It is observational, not randomized. There is no placebo arm, no blinding, and no control over dose or setting. Participants choose to use the program and self-report their outcomes, which introduces the selection and reporting effects that randomized trials exist to remove. The project cannot establish that psilocybin causes a given improvement, and it should not be read as an efficacy study. What it can do is document safety signals, adverse and challenging experiences, and substance-use patterns across a population far larger and more representative than any trial cohort, and do so prospectively rather than through after-the-fact surveys. Because the award runs five years, results are not expected until around 2031.
Why it matters now
Oregon is the first state to run a legal psilocybin program, and Colorado has followed with its own framework. More states are weighing similar measures, and they are doing so with almost no real-world safety data, because until this grant there was none being collected with federal rigor. The OPEN project is explicitly designed to inform those decisions. It is the evidence base that policymakers in the next states will lean on, which gives a single academic grant outsized influence over how the regulated psilocybin model spreads or stalls.
The contrast with the commercial side of the field is the cleanest way to see the stakes. While Compass Pathways advances a synthetic psilocybin formulation toward an FDA filing on the strength of controlled Phase 3 data, the first federal dollars are going to the opposite question: what happens when psilocybin leaves the controlled setting entirely and becomes a service people buy. Both questions need answering. Until February, only one of them had any federal money behind it. The Oregon study is the start of the other.